Phentermine: Clinical Trials

7 trials of Phentermine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 withdrawn. 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 17Completed 6, Withdrawn 1

Follow Phentermine: new trials by email Literature Review of Phentermine trials Research Report on Phentermine

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users
Pitolisant, Placebos, Phentermine - Healthy, Drug Abuse
Phase 1CompletedBioprojet432017-03-152017-11-13
A Study to Evaluate Abuse Potential of Istradefylline
Istradefylline, Phentermine 45 mg, Placebo - Drug Abuse
Phase 1CompletedKyowa Kirin Co., Ltd.422016-01-012024-04-25
FDA Approved Medication to Reduce Binge Eating and/or Purging
Phentermine/Topiramate-First, Placebo - Binge Eating Disorder, Bulimia Nervosa
Phase 1CompletedStanford University222015-10-302018-05-14
Topiramate-Phentermine Combinations for Cocaine Dependence
Cocaine, Placebo, Phentermine - Cocaine Use Disorder
Phase 1CompletedUniversity of Kentucky382014-09-012019-11-27
Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214
TC-5214, TC-5214 Placebo, Ketamine - Drug Abuse, Healthy
Phase 1WithdrawnAstraZeneca2012-01-012012-03-22
A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment
Topirmate and Phentermine - Renal Impairment
Phase 1CompletedVIVUS LLC322008-10-012009-12-01
Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
topiramate, phentermine - Obesity
Phase 1CompletedVIVUS LLC642007-07-012011-06-08

Conditions studied

Substance-Related Disorders (3)  ·  Binge-Eating Disorder (1)  ·  Bulimia (1)  ·  Bulimia Nervosa (1)  ·  Obesity (1)  ·  Renal Insufficiency (1)

Sponsors

VIVUS LLC (2)  ·  AstraZeneca (1)  ·  Bioprojet (1)  ·  Kyowa Kirin Co., Ltd. (1)  ·  Stanford University (1)  ·  University of Kentucky (1)

Countries

United States (5)  ·  Canada (1)

Top investigators

Brendan Smyth, MD (1)  ·  Craig R Rush, Ph.D. (1)  ·  Debra L Safer, MD (1)  ·  Hans A Eriksson, MD (1)  ·  Michael B. McDonnell, MD (1)  ·  Pierre Geoffroy, MDCM, MSC, FCFP (1)  ·  Sarah Adler, PsyD (1)  ·  Shebani Sethi, MD (1)  ·  Shiyin Yee, PhD (1)  ·  Wesley W Day, PhD (1)

Results publications

PMID 29038069, PMID 31626696, PMID 31721257

NIH funding

R01DA032254 (1)